Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.38 |
| ▸ | NPC1 | O15118 | 6/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | HTT | P42858 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11956545 | 0.69 | RAB9A (0.40) | RAB9ANPC1NTSR1KDM4EHTT | |
| SCHEMBL1925010 | 0.68 | KDM4E (0.37) | RAB9ANPC1NTSR1KDM4EHTT | |
| SCHEMBL14164175 | 0.64 | RAB9A (0.40) | RAB9ANPC1NTSR1KDM4EHTT | |
| SCHEMBL24775380 | 0.62 | KDM4E (0.43) | RAB9ANPC1NTSR1KDM4EHTT | |
| SCHEMBL2647551 | 0.61 | CYP2A6 (0.55) | CYP11B1CYP11B2PSMB5CYP3A4 | |
| SCHEMBL4144064 | 0.61 | ALDH1A1 (0.44) | RAB9ANPC1NTSR1KDM4EHTT | |
| SCHEMBL1752891 | 0.60 | RAB9A (0.42) | RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2956668 | 0.60 | HTT (0.41) | RAB9ANPC1NTSR1KDM4EHTT | |
| SCHEMBL11978672 | 0.60 | CYP2A6 (0.53) | CYP11B1CYP11B2PSMB5CYP3A4 | |
| SCHEMBL598686 | 0.60 | TSHR (0.53) | RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168120-A1 | SALTS OF PYRIDAZINE COMPOUNDS | NEUROMEDIX INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| EP-2015751-A2 | SALTS OF PYRIDAZINE COMPOUNDS | Northwestern University (US) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007127448-A2 | SALTS OF PYRIDAZINE COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168120-A1 | SALTS OF PYRIDAZINE COMPOUNDS | PTMS, TST, SRMS | RAB9A 2898/4885NPC1 2443/4885NTSR1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.